References
- Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011;31(1):1–8. dosi:10.1002/pd.2637.
- Spencer K, Yu CKH, Cowans NJ, et al. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn. 2005;25(10):949–953. doi:10.1002/pd.1251.
- Kumar M, Singh S, Sharma K, et al. Adverse fetal outcome: is first trimester ultrasound and Doppler better predictor than biomarkers? J Matern Fetal Neonatal Med. 2017;30(12):1410–1416.
- Aplin JD, Myers JE, Timms K, et al. Tracking placental development in health and disease. Nat Rev Endocrinol. 2020;16(9):479–494.
- Fisher SJ, McMaster M, Roberts JM. The placenta in normal pregnancy and preeclampsia. In: Taylor RT, Cunningham FG, Roberts JM, Lindheimer MD, editors. Chesley’s hypertensive disorders in pregnancy. 4th ed. London (UK): Academic Press; 2015. p. 81–112.
- Fonseca EB, Celik E, Parra M, et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007;357(5):462–469. doi:10.1056/NEJMoa067815.
- Klein K, Rode L, Nicolaides KH, et al. Vaginal micronized progesterone and risk of preterm delivery in high-risk twin pregnancies: secondary analysis of a placebo-controlled randomized trial and meta-analysis. Ultrasound Obstet Gynecol. 2011;38(3):281–287. doi:10.1002/uog.9092.
- Halasz M, Szekeres-Bartho J. The role of progesterone in implantation and trophoblast invasion. J Reprod Immunol. 2013;97(1):43–50. doi: 10.1016/j.jri.2012.10.011.
- Seeber BE, Barnhart KT. Suspected ectopic pregnancy. Obstet Gynecol. 2006;107(2 Pt 1):399–413.
- Tal RT. Endocrinology of pregnancy. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. South Dartmouth (MA): MDText.com, Inc.; 2000.
- Baulieu EE. Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor. Science. 1989;245(4924):1351–1357. doi:10.1126/science.2781282.
- Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn. 2008;28(1):7–10. doi:10.1002/pd.1890.
- Tul N, Pusenjak S, Osredkar J, et al. Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. Prenat Diagn. 2003;23(12):990–996. doi:10.1002/pd.735.
- Smith GCS, Shah I, Crossley JA, et al. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol. 2006;107(1):161–166. doi:10.1097/01.AOG.0000191302.79560.d8.
- Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER trial). Am J Obstet Gynecol. 2004;191(4):1446–1451. doi:10.1016/j.ajog.2004.06.052.
- Kavak ZN, Basgul A, Elter K, et al. The efficacy of first-trimester PAPP-A and free beta hCG levels for predicting adverse pregnancy outcome. J Perinat Med. 2006;34(2):145–148.
- Morssink LP, Kornman LH, Hallahan TW, et al. Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn. 1998;18(2):147–152. doi:10.1002/(SICI)1097-0223(199802)18:2<147::AID-PD231>3.0.CO;2-W.
- Lawrence JB, Oxvig C, Overgaard MT, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A. 1999;96(6):3149–3153. doi:10.1073/pnas.96.6.3149.
- van Kleffens M, Groffen C, Lindenbergh-Kortleve DJ, et al. The IGF system during fetal–placental development of the mouse. Mol Cell Endocrinol. 1998;140(1–2):129–135. doi:10.1016/s0303-7207(98)00041-0.
- Conover CA, Bale LK, Overgaard MT, et al. Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development. 2004;131(5):1187–1194. doi:10.1242/dev.00997.
- Irwin JC, Suen LF, Martina NA, et al. Role of the IGF system in trophoblast invasion and pre-eclampsia. Hum Reprod. 1999;14(Suppl. 2):90–96. doi:10.1093/humrep/14.suppl_2.90.
- Wang J, Liu S, Qin HM, et al. Pregnancy-associated plasma protein A up-regulated by progesterone promotes adhesion and proliferation of trophoblastic cells. Int J Clin Exp Pathol. 2014;7(4):1427–1437.
- Coomarasamy A, Williams H, Truchanowicz E, et al. PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages – a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation. Health Technol Assess. 2016;20(41):1–92. doi:10.3310/hta20410.
- Coomarasamy A, Harb HM, Devall AJ, et al. Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT. Health Technol Assess. 2020;24(33):1–70. doi:10.3310/hta24330.
- Piette PCM. The pharmacodynamics and safety of progesterone. Best Pract Res Clin Obstet Gynaecol. 2020;69:13–29.
- Devall AJ, Coomarasamy A. Sporadic pregnancy loss and recurrent miscarriage. Best Pract Res Clin Obstet Gynaecol. 2020;69:30–39.